Research
Energy balance
INV-202 produced a significant mean weight loss of 3.5 kg (3.3% compared with placebo participants who gained a mean 0.6 kg [0.5%]).
INV-202 may be an effective treatment for weight loss in individuals with metabolic syndrome.
StrongSupportsmedium confidence
INV-202 produced a significant mean weight loss of 3.5 kg (3.3% compared with placebo participants who gained a mean 0.6 kg [0.5%]).
Why this rating
Based on study design from abstract.
Source
Effects of <scp>CB1R</scp> inverse agonist, <scp>INV</scp> ‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study
Glenn Crater et al. · Diabetes Obesity and Metabolism · 2023
rct · n=37Cited 40×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →